New imaging agent aims to spot hidden cancer in neck lymph nodes

NCT ID NCT05901545

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests whether a radioactive imaging agent called 111In-panitumumab can help find cancer that has spread to lymph nodes in people with head and neck cancer. The agent binds to a protein common on cancer cells and lights up on a special scan. About 30 participants will receive the agent before surgery, and doctors will compare the scan results with what they find during the operation. The main goal is to check safety and see if the agent improves detection of cancerous lymph nodes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Indium In 111 panitumumab (a radioactive imaging agent)
What this could lead to
If successful, this could improve the accuracy of detecting cancer spread to lymph nodes, helping surgeons remove the right nodes and potentially improving survival outcomes.
What could go wrong
This is an early phase I trial with only 30 participants, so it is too soon to know if the imaging agent works better than current methods. There may be side effects from the radioactive substance or the antibody.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Vanderbilt University/Ingram Cancer Center

    RECRUITING

    Nashville, Tennessee, 37232, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.